Faisal Khurshid
Stock Analyst at Leerink Partners
(0)
# 4312
Out of 5,325 analysts
20
Total ratings
25.00%
Success rate
-13.06%
Average return
Main Sectors:
Top Industries:
| Name | Action | Price Target | Current | % Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
IRWD Ironwood Pharmaceuti... | Maintains: Market Perform | 3 1 | 0.77 | 29.87% | 2 | Apr 14, 2025 | |
SYRE Spyre Therapeutics | Initiates Coverage On: Outperform | 45 | 14.22 | 216.46% | 1 | Apr 8, 2025 | |
NRIX Nurix Therapeutics | Initiates Coverage On: Market Perform | 16 | 11.64 | 37.46% | 1 | Mar 17, 2025 | |
STTK Shattuck Labs | Initiates Coverage On: Outperform | 4 | 0.86 | 365.12% | 1 | Mar 17, 2025 | |
PLRX Pliant Therapeutics | Downgrades: Market Perform | 33 2 | n/a | n/a | 2 | Mar 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Outperform | 16 | 3.52 | 354.55% | 1 | Feb 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Outperform | 60 60 | 30.72 | 95.31% | 2 | Dec 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Outperform | 80 | 68.46 | 16.86% | 1 | Dec 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Outperform | 15 | 1.44 | 941.67% | 1 | Nov 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Assumes: Outperform | 7 | 6.28 | 11.46% | 1 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Assumes: Outperform | 45 | 17.14 | 162.54% | 1 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Market Perform | 24 | 25.5 | -5.88% | 1 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Outperform | 7 | 1.38 | 407.25% | 1 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Assumes: Outperform | 8 | 4.62 | 73.16% | 1 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Assumes: Outperform | 5 | 1.11 | 350.45% | 1 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Market Perform | 17 21 | n/a | n/a | 1 | Mar 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Outperform | 11 | n/a | n/a | 1 | Mar 21, 2023 |